HOME >> BIOLOGY >> NEWS
Novel Two-Antibody Strategy To Fight Cancer Awarded Patent

Researchers at the University of Pennsylvania Medical Center today were awarded patent number 5,824,311 for a new technology that has shown the potential in laboratory studies to cure breast and other major cancers linked to certain abnormal genes.

Broadly viewed, the approach targets cancer-causing receptor molecules found on the surface of tumor cells with two different antibodies that bind to the molecules, fatally disabling the receptor's activity and leading to the cancer cell's death.

The specific application of the concept detailed in the patent employs a pair of antibodies against a receptor protein called p185. The p185 protein assembles into a two-protein receptor complex thought to be involved in stimulating the uncontrolled growth of a number of dangerous cancers, including those of the breast and the pancreas. Instructions for producing the p185 protein in the cell are encoded by a gene known as neu.

The recently approved anti-breast-cancer drug Herceptin also acts on the receptor produced by the neu gene but brings only one antibody to bear on it. Experiments in rodent models, however, showed that a two-antibody strategy was significantly more powerful.

"In our two-antibody studies, we were able to achieve cures of tumors as opposed to simply reducing tumor growth," says Mark I. Greene, MD, PhD, a professor of pathology and laboratory medicine in whose laboratory the work was conducted. "In our experience, a single antibody against the receptor only diminishes the growth of tumor cells, whereas two antibodies disable the receptor so effectively that the cells perish."

Receptor proteins are convoluted structures with many sites -- called epitopes -- to which a wide array of antibodies can bind. It is possible for some of these sites not to be involved in the activity of the protein. Also, antibodies that bind in different ways to the same site can limit each other's effectiveness. Signif
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
20-Oct-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel Two Antibody Strategy Fight Cancer Awarded Patent

(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
(Date:5/29/2015)... May 29, 2015 Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces that results of a large, ... melanoma patients with hepatic metastases with the Delcath ... in an on-line abstract at the American Society ...
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences ® ... the promise of precision medicine, today announced the ... the clinical utility of Caris Molecular Intelligence ® ... in helping to identify targeted treatment options for ... of the studies, results of which are to ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Results from ... talimogene laherparepvec and its ability to reduce the size ... have been published in the Journal of Clinical Oncology. ... with stages IIIB, IIIC and IV melanoma, a potentially ... the study was to evaluate the safety and efficacy ...
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "Alzheimer ...  to their offering.       (Logo: ... challenge in management. With nearly 8 million ... major markets of the world and anticipated ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
Cached News: